Connect with others who understand.

Sign up Log in
Resources
About mySMAteam
Powered By
SMA
NEWS

Breathing Remains Stable for Infants With SMA Type 1 Taking Spinraza, Study Shows

Medically reviewed by Evelyn O. Berman, M.D.
Written by Brooke Dulka, Ph.D.
Posted on January 6, 2022

  • Nusinersen, sold as Spinraza, has been shown to prevent decline in breathing abilities in some infants with spinal muscular atrophy (SMA) type 1.
  • In a recent study, none of the infants receiving the treatment showed signs of improvement in their breathing after two years of treatment.
  • Researchers concluded that further real-world study is necessary to determine if starting treatment earlier will have better outcomes.

Infants with SMA type 1 treated with nusinersen can maintain the same level of breathing or respiration over two years, according to a new study. Typically, infants with SMA type 1 — the most severe form of the condition — experience a rapid decline in their breathing abilities as the condition progresses. The median survival for infants with SMA type 1 is 8 to 13.5 months. Respiratory failure is the most common cause of death.

Sold as Spinraza, nusinersen is the first disease-modifying therapy for SMA. It was approved by the U.S. Food and Drug Administration (FDA) in 2016.

For the study — conducted by Dr. Moran Lavie and their colleagues at Tel Aviv University in Israel — 20 infants with SMA type 1 were assessed both before and after two years of nusinersen treatment. Among the participants, 16 infants were already on assisted ventilation at the start of the study; the other four were not.

Share your thoughts with others. Click here to add a comment.

During the two years, the researchers observed several outcomes. These included:

  • All of the participants who were on ventilation when they started treatment remained clinically stable, maintaining a similar level and type of ventilatory support.
  • The four infants who were not on ventilation needed to start ventilation.
  • Two infants died from acute respiratory failure.
  • One infant sustained a severe brain injury.
  • Four of the infants had recurrent or chronic collapse of the lung.

“Our experience was that most patients were stable in their need for assisted ventilation and did not worsen as expected given the natural history of the disease, nor did they improve as one would hope,” the authors of the study wrote.

They noted that further studies are necessary to see whether starting treatment with nusinersen earlier might lead to better respiratory outcomes.

Posted on January 6, 2022
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
Evelyn O. Berman, M.D. is a neurology and pediatric specialist and treats disorders of the brain in children. Review provided by VeriMed Healthcare Network. Learn more about her here.
Brooke Dulka, Ph.D. is a freelance science writer and editor. She received her doctoral training in biological psychology at the University of Tennessee. Learn more about her here.

Recent Articles

Spinal muscular atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness ...

What Is Spinal Muscular Atrophy (SMA)?

Spinal muscular atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness ...
Until recently, treatments for spinal muscular atrophy (SMA) could manage only symptoms. Doctors ...

Spinal Muscular Atrophy Treatment and Therapy Options

Until recently, treatments for spinal muscular atrophy (SMA) could manage only symptoms. Doctors ...
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes muscle weakness. SM...

Symptoms of Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes muscle weakness. SM...
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by muscle weaknes...

Causes of Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by muscle weaknes...
Spinal muscular atrophy (SMA), a genetic neuromuscular disorder that leads to muscle weakness, is...

Scoliosis in Spinal Muscular Atrophy

Spinal muscular atrophy (SMA), a genetic neuromuscular disorder that leads to muscle weakness, is...
4 Ways To Reduce the Cost of Medication The price of medication affects the quality of life f...

4 Ways To Reduce the Cost of Medication (VIDEO)

4 Ways To Reduce the Cost of Medication The price of medication affects the quality of life f...
SMA News

Thank you for subscribing!

Become a member to get even more: